| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Nephropathies | 128 | 2024 | 973 | 17.280 |
Why?
|
| Diabetes Mellitus, Type 1 | 126 | 2024 | 3415 | 9.410 |
Why?
|
| Kidney Failure, Chronic | 49 | 2024 | 2472 | 6.930 |
Why?
|
| Albuminuria | 45 | 2020 | 658 | 5.050 |
Why?
|
| Proteinuria | 25 | 2017 | 607 | 3.070 |
Why?
|
| Glomerular Filtration Rate | 34 | 2021 | 2178 | 2.910 |
Why?
|
| Diabetes Mellitus, Type 2 | 78 | 2022 | 12149 | 2.690 |
Why?
|
| Kidney | 27 | 2021 | 7048 | 2.170 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 9 | 2018 | 256 | 1.870 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 6 | 2016 | 344 | 1.690 |
Why?
|
| Polymorphism, Genetic | 32 | 2007 | 4243 | 1.690 |
Why?
|
| Cystatin C | 15 | 2015 | 270 | 1.520 |
Why?
|
| Disease Progression | 43 | 2024 | 13510 | 1.450 |
Why?
|
| Hyperglycemia | 14 | 2021 | 1376 | 1.330 |
Why?
|
| Creatinine | 18 | 2018 | 1899 | 1.260 |
Why?
|
| Genetic Linkage | 19 | 2008 | 2341 | 1.120 |
Why?
|
| Genetic Predisposition to Disease | 43 | 2018 | 17904 | 1.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 2024 | 585 | 0.960 |
Why?
|
| Kidney Function Tests | 9 | 2017 | 679 | 0.930 |
Why?
|
| Cystatins | 7 | 2008 | 55 | 0.890 |
Why?
|
| Kidney Diseases | 7 | 2018 | 2091 | 0.800 |
Why?
|
| Uric Acid | 5 | 2013 | 807 | 0.780 |
Why?
|
| Chromosome Mapping | 18 | 2009 | 4615 | 0.770 |
Why?
|
| 17-Hydroxysteroid Dehydrogenases | 1 | 2021 | 56 | 0.770 |
Why?
|
| Peptidyl-Dipeptidase A | 6 | 2007 | 362 | 0.740 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2020 | 60 | 0.710 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2018 | 2242 | 0.710 |
Why?
|
| Diabetic Retinopathy | 20 | 2009 | 1274 | 0.700 |
Why?
|
| Adult | 157 | 2024 | 221210 | 0.680 |
Why?
|
| Polymorphism, Single Nucleotide | 18 | 2024 | 15936 | 0.680 |
Why?
|
| Renal Insufficiency | 3 | 2024 | 809 | 0.650 |
Why?
|
| Chromosomes, Human, Pair 20 | 6 | 2008 | 127 | 0.630 |
Why?
|
| Haplotypes | 13 | 2009 | 2713 | 0.610 |
Why?
|
| Genetic Variation | 10 | 2024 | 6567 | 0.600 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2011 | 431 | 0.580 |
Why?
|
| Humans | 252 | 2024 | 761596 | 0.560 |
Why?
|
| Middle Aged | 110 | 2024 | 220921 | 0.560 |
Why?
|
| Kidney Tubules, Proximal | 3 | 2021 | 383 | 0.550 |
Why?
|
| Male | 159 | 2024 | 360846 | 0.550 |
Why?
|
| MicroRNAs | 5 | 2024 | 3816 | 0.550 |
Why?
|
| Diabetic Neuropathies | 6 | 2015 | 405 | 0.540 |
Why?
|
| Risk Factors | 57 | 2024 | 74213 | 0.530 |
Why?
|
| Female | 161 | 2024 | 392705 | 0.530 |
Why?
|
| Case-Control Studies | 29 | 2021 | 22176 | 0.500 |
Why?
|
| Chromosomes, Human, Pair 2 | 3 | 2013 | 313 | 0.480 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2021 | 4352 | 0.480 |
Why?
|
| Endpoint Determination | 1 | 2017 | 590 | 0.460 |
Why?
|
| Neuroblastoma | 1 | 2022 | 1250 | 0.460 |
Why?
|
| Amino Acids, Essential | 1 | 2014 | 26 | 0.460 |
Why?
|
| Receptors, Angiotensin | 3 | 2002 | 141 | 0.450 |
Why?
|
| Genotype | 27 | 2013 | 12990 | 0.450 |
Why?
|
| Pyrophosphatases | 2 | 2006 | 142 | 0.450 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 4 | 2012 | 1516 | 0.440 |
Why?
|
| Diabetic Angiopathies | 12 | 1997 | 803 | 0.440 |
Why?
|
| Kidney Glomerulus | 2 | 2016 | 568 | 0.440 |
Why?
|
| Phosphoric Diester Hydrolases | 2 | 2006 | 201 | 0.440 |
Why?
|
| Blood Proteins | 4 | 2024 | 1173 | 0.430 |
Why?
|
| Proteomics | 7 | 2024 | 3848 | 0.430 |
Why?
|
| Alleles | 17 | 2011 | 6864 | 0.430 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2017 | 857 | 0.420 |
Why?
|
| Age of Onset | 18 | 2009 | 3306 | 0.420 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2013 | 535 | 0.420 |
Why?
|
| Diabetes Mellitus | 23 | 2024 | 5841 | 0.420 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2015 | 629 | 0.420 |
Why?
|
| Uremia | 1 | 2014 | 201 | 0.420 |
Why?
|
| Nuclear Family | 8 | 2006 | 311 | 0.410 |
Why?
|
| Cell Cycle Proteins | 2 | 2022 | 3449 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 13 | 2 | 2011 | 192 | 0.400 |
Why?
|
| Blood Pressure | 20 | 2018 | 8481 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 7 | 3 | 2008 | 310 | 0.390 |
Why?
|
| Diabetes Complications | 10 | 2002 | 1315 | 0.380 |
Why?
|
| Urine | 1 | 2013 | 362 | 0.380 |
Why?
|
| Esterases | 2 | 2001 | 98 | 0.370 |
Why?
|
| DNA | 12 | 2006 | 7213 | 0.370 |
Why?
|
| Hypertension | 22 | 2012 | 8540 | 0.360 |
Why?
|
| DNA, Intergenic | 1 | 2011 | 105 | 0.360 |
Why?
|
| Apoptosis | 3 | 2024 | 9490 | 0.340 |
Why?
|
| Reference Values | 16 | 2009 | 4920 | 0.340 |
Why?
|
| Fibrinogen | 4 | 1997 | 888 | 0.340 |
Why?
|
| Renin-Angiotensin System | 4 | 2012 | 737 | 0.340 |
Why?
|
| Follow-Up Studies | 33 | 2018 | 39106 | 0.330 |
Why?
|
| Losartan | 1 | 2011 | 265 | 0.330 |
Why?
|
| Pedigree | 13 | 2013 | 4542 | 0.330 |
Why?
|
| Insulin | 24 | 2010 | 6597 | 0.330 |
Why?
|
| Nitric Oxide Synthase | 3 | 2003 | 908 | 0.330 |
Why?
|
| Dipeptidases | 1 | 2008 | 38 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 8 | 3 | 2006 | 453 | 0.310 |
Why?
|
| Hyperuricemia | 1 | 2011 | 222 | 0.310 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 393 | 0.300 |
Why?
|
| Metabolomics | 2 | 2017 | 1659 | 0.300 |
Why?
|
| Receptors, Drug | 1 | 2008 | 157 | 0.300 |
Why?
|
| Blood Glucose | 20 | 2018 | 6391 | 0.300 |
Why?
|
| Models, Genetic | 8 | 2013 | 3442 | 0.290 |
Why?
|
| Proportional Hazards Models | 9 | 2018 | 12463 | 0.290 |
Why?
|
| Point Mutation | 4 | 2006 | 1595 | 0.280 |
Why?
|
| Apolipoproteins E | 3 | 2000 | 1443 | 0.280 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2007 | 457 | 0.280 |
Why?
|
| Prognosis | 13 | 2020 | 29629 | 0.280 |
Why?
|
| Genome-Wide Association Study | 11 | 2019 | 12690 | 0.270 |
Why?
|
| Angiotensinogen | 2 | 1998 | 161 | 0.270 |
Why?
|
| Polymorphism, Restriction Fragment Length | 5 | 1995 | 767 | 0.270 |
Why?
|
| Autonomic Nervous System Diseases | 3 | 1995 | 269 | 0.270 |
Why?
|
| Time Factors | 20 | 2018 | 39969 | 0.260 |
Why?
|
| Chromosomes, Human, Pair 3 | 3 | 2008 | 322 | 0.260 |
Why?
|
| Phosphoproteins | 4 | 1999 | 2448 | 0.260 |
Why?
|
| Family Health | 6 | 2009 | 1257 | 0.260 |
Why?
|
| Risk | 20 | 2017 | 9610 | 0.260 |
Why?
|
| Patient Selection | 2 | 2017 | 4244 | 0.250 |
Why?
|
| Genome, Human | 4 | 2009 | 4425 | 0.250 |
Why?
|
| Fibrin | 3 | 1997 | 507 | 0.250 |
Why?
|
| Symporters | 1 | 2008 | 363 | 0.240 |
Why?
|
| Chemokine CCL5 | 1 | 2005 | 214 | 0.240 |
Why?
|
| Nuclear Proteins | 6 | 2003 | 5799 | 0.240 |
Why?
|
| Genes, Dominant | 6 | 2000 | 852 | 0.240 |
Why?
|
| Transforming Growth Factor beta | 2 | 2022 | 1964 | 0.240 |
Why?
|
| Aryldialkylphosphatase | 2 | 2001 | 64 | 0.230 |
Why?
|
| Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) | 1 | 2004 | 11 | 0.230 |
Why?
|
| Multifactorial Inheritance | 1 | 2012 | 1387 | 0.230 |
Why?
|
| Cohort Studies | 20 | 2021 | 41495 | 0.230 |
Why?
|
| Receptor, Insulin | 6 | 2010 | 836 | 0.230 |
Why?
|
| Predictive Value of Tests | 8 | 2018 | 15266 | 0.230 |
Why?
|
| Poland | 14 | 2007 | 198 | 0.220 |
Why?
|
| Adolescent | 48 | 2016 | 88326 | 0.220 |
Why?
|
| Multivariate Analysis | 6 | 2017 | 12059 | 0.220 |
Why?
|
| Gene Frequency | 9 | 2006 | 3606 | 0.220 |
Why?
|
| Receptors, CCR5 | 1 | 2005 | 486 | 0.220 |
Why?
|
| DNA-Binding Proteins | 8 | 2003 | 9610 | 0.220 |
Why?
|
| Linkage Disequilibrium | 7 | 2008 | 1998 | 0.210 |
Why?
|
| Chemokine CCL2 | 3 | 2018 | 605 | 0.210 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 6 | 1995 | 1741 | 0.210 |
Why?
|
| Transcription Factors | 7 | 2003 | 12130 | 0.210 |
Why?
|
| Inflammation | 2 | 2021 | 10774 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2011 | 410 | 0.210 |
Why?
|
| Lymphocytes | 5 | 2003 | 2612 | 0.200 |
Why?
|
| Interleukin-6 | 3 | 2010 | 3208 | 0.200 |
Why?
|
| Aged | 40 | 2024 | 169310 | 0.200 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2003 | 276 | 0.200 |
Why?
|
| Endostatins | 1 | 2022 | 168 | 0.190 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 4 | 1999 | 166 | 0.190 |
Why?
|
| Genetic Markers | 11 | 2004 | 2601 | 0.190 |
Why?
|
| Signal Transduction | 6 | 2024 | 23447 | 0.180 |
Why?
|
| Mutation | 12 | 2019 | 30053 | 0.180 |
Why?
|
| Aldehyde Reductase | 2 | 2000 | 71 | 0.180 |
Why?
|
| Genomic Imprinting | 1 | 2002 | 329 | 0.180 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2002 | 436 | 0.180 |
Why?
|
| Haptoglobins | 1 | 2001 | 166 | 0.180 |
Why?
|
| Antiporters | 2 | 1992 | 277 | 0.180 |
Why?
|
| Base Sequence | 11 | 2004 | 12441 | 0.170 |
Why?
|
| Exons | 8 | 2003 | 2391 | 0.170 |
Why?
|
| Glomerular Basement Membrane | 1 | 2019 | 36 | 0.170 |
Why?
|
| Family | 8 | 2012 | 3195 | 0.170 |
Why?
|
| Collagen Type IV | 1 | 2019 | 126 | 0.160 |
Why?
|
| Prospective Studies | 15 | 2019 | 54423 | 0.160 |
Why?
|
| Lod Score | 9 | 2007 | 600 | 0.160 |
Why?
|
| Coronary Disease | 7 | 2013 | 5914 | 0.160 |
Why?
|
| Lectins, C-Type | 1 | 2022 | 585 | 0.160 |
Why?
|
| Cholesterol | 4 | 2018 | 2905 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 2898 | 0.160 |
Why?
|
| Protein Kinase C | 1 | 2003 | 1202 | 0.160 |
Why?
|
| Vitamin D-Binding Protein | 1 | 1999 | 131 | 0.160 |
Why?
|
| Up-Regulation | 3 | 2021 | 4125 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 4 | 2003 | 27 | 0.150 |
Why?
|
| Survival Rate | 5 | 2021 | 12723 | 0.150 |
Why?
|
| Fibroblasts | 2 | 2021 | 4142 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 9420 | 0.150 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 4 | 2003 | 92 | 0.150 |
Why?
|
| Focal Adhesions | 1 | 2018 | 115 | 0.150 |
Why?
|
| Fibrinolysis | 2 | 1997 | 332 | 0.140 |
Why?
|
| France | 1 | 2018 | 497 | 0.140 |
Why?
|
| New England | 1 | 2020 | 1054 | 0.140 |
Why?
|
| Finland | 1 | 2018 | 607 | 0.140 |
Why?
|
| Telomere-Binding Proteins | 1 | 2018 | 119 | 0.140 |
Why?
|
| Trans-Activators | 3 | 2006 | 2856 | 0.140 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2000 | 543 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 3 | 2006 | 126 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 4 | 2003 | 174 | 0.140 |
Why?
|
| Longitudinal Studies | 5 | 2020 | 14608 | 0.140 |
Why?
|
| Glucose Tolerance Test | 6 | 1996 | 1178 | 0.140 |
Why?
|
| Promoter Regions, Genetic | 7 | 2013 | 5790 | 0.130 |
Why?
|
| Cardiovascular System | 2 | 1995 | 834 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 7 | 2002 | 6075 | 0.130 |
Why?
|
| Denmark | 1 | 2018 | 771 | 0.130 |
Why?
|
| Cytokines | 2 | 2008 | 7396 | 0.130 |
Why?
|
| Minisatellite Repeats | 1 | 1996 | 163 | 0.130 |
Why?
|
| Risk Assessment | 7 | 2018 | 23996 | 0.120 |
Why?
|
| Incidence | 13 | 2015 | 21355 | 0.120 |
Why?
|
| Linear Models | 3 | 2017 | 5872 | 0.120 |
Why?
|
| Autoantigens | 1 | 2019 | 891 | 0.120 |
Why?
|
| Homeodomain Proteins | 2 | 2006 | 2418 | 0.120 |
Why?
|
| Sex Characteristics | 1 | 2005 | 2639 | 0.120 |
Why?
|
| Odds Ratio | 8 | 2015 | 9647 | 0.120 |
Why?
|
| Serum Albumin | 2 | 2012 | 672 | 0.120 |
Why?
|
| Epidermal Growth Factor | 1 | 2018 | 702 | 0.120 |
Why?
|
| Molecular Sequence Data | 10 | 2002 | 17635 | 0.120 |
Why?
|
| Nerve Growth Factors | 1 | 2018 | 564 | 0.120 |
Why?
|
| Genomics | 2 | 2008 | 5821 | 0.120 |
Why?
|
| Disease Susceptibility | 7 | 2006 | 1787 | 0.120 |
Why?
|
| Boston | 4 | 2015 | 9327 | 0.120 |
Why?
|
| Reperfusion Injury | 1 | 2021 | 1023 | 0.120 |
Why?
|
| Chemistry, Clinical | 1 | 1994 | 64 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 12 | 3 | 2001 | 430 | 0.120 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 1999 | 858 | 0.120 |
Why?
|
| GTP-Binding Proteins | 1 | 1998 | 951 | 0.110 |
Why?
|
| Heterozygote | 4 | 2003 | 2787 | 0.110 |
Why?
|
| DNA Probes | 4 | 1998 | 541 | 0.110 |
Why?
|
| Obesity | 9 | 2006 | 12947 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 5 | 2 | 2007 | 386 | 0.110 |
Why?
|
| Down-Regulation | 1 | 2021 | 2919 | 0.110 |
Why?
|
| Kininogen, High-Molecular-Weight | 1 | 2013 | 6 | 0.110 |
Why?
|
| Glutamate-Ammonia Ligase | 1 | 2013 | 75 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 789 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 1995 | 343 | 0.110 |
Why?
|
| Age Factors | 14 | 2008 | 18399 | 0.110 |
Why?
|
| Receptors, Virus | 2 | 2014 | 640 | 0.110 |
Why?
|
| Fibrosis | 1 | 2020 | 2049 | 0.110 |
Why?
|
| Microsatellite Repeats | 3 | 2008 | 784 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 20100 | 0.100 |
Why?
|
| Siblings | 2 | 2008 | 825 | 0.100 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 783 | 0.100 |
Why?
|
| Models, Biological | 5 | 2017 | 9469 | 0.100 |
Why?
|
| Early Diagnosis | 1 | 2018 | 1186 | 0.100 |
Why?
|
| Pregnancy in Diabetics | 2 | 1991 | 197 | 0.100 |
Why?
|
| Regression Analysis | 8 | 2003 | 6345 | 0.100 |
Why?
|
| HLA-DR4 Antigen | 1 | 1992 | 22 | 0.100 |
Why?
|
| HLA-DR3 Antigen | 1 | 1992 | 24 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1993 | 350 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 2 | 2010 | 901 | 0.100 |
Why?
|
| Young Adult | 11 | 2017 | 59260 | 0.100 |
Why?
|
| Ticlopidine | 1 | 1997 | 730 | 0.100 |
Why?
|
| Introns | 4 | 2006 | 981 | 0.100 |
Why?
|
| Inflammation Mediators | 2 | 2019 | 1886 | 0.100 |
Why?
|
| DNA Primers | 3 | 2004 | 2820 | 0.100 |
Why?
|
| Membrane Glycoproteins | 2 | 2014 | 3701 | 0.100 |
Why?
|
| Mass Spectrometry | 3 | 2014 | 2192 | 0.100 |
Why?
|
| Child | 17 | 2013 | 80158 | 0.100 |
Why?
|
| Peptides | 3 | 2010 | 4358 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2013 | 638 | 0.090 |
Why?
|
| Chemokine CXCL10 | 2 | 2010 | 316 | 0.090 |
Why?
|
| Child, Preschool | 11 | 2012 | 42232 | 0.090 |
Why?
|
| Antihypertensive Agents | 3 | 2012 | 2024 | 0.090 |
Why?
|
| Macromolecular Substances | 3 | 1998 | 1434 | 0.090 |
Why?
|
| Acetylglucosaminidase | 1 | 2010 | 66 | 0.090 |
Why?
|
| Indians, North American | 1 | 2014 | 352 | 0.090 |
Why?
|
| Insulin Resistance | 5 | 2000 | 3964 | 0.090 |
Why?
|
| Molecular Sequence Annotation | 1 | 2013 | 522 | 0.090 |
Why?
|
| Cells, Cultured | 7 | 2015 | 18966 | 0.090 |
Why?
|
| Maternal Age | 3 | 1995 | 809 | 0.090 |
Why?
|
| Autonomic Nervous System | 1 | 2015 | 703 | 0.090 |
Why?
|
| Drug Synergism | 1 | 2014 | 1757 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 3415 | 0.090 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2010 | 84 | 0.090 |
Why?
|
| DNA Methylation | 1 | 2024 | 4399 | 0.090 |
Why?
|
| Retinal Neovascularization | 1 | 1993 | 288 | 0.080 |
Why?
|
| Glucose Intolerance | 3 | 1999 | 575 | 0.080 |
Why?
|
| Podocytes | 1 | 2014 | 405 | 0.080 |
Why?
|
| Nonlinear Dynamics | 1 | 2012 | 492 | 0.080 |
Why?
|
| Logistic Models | 5 | 2015 | 13255 | 0.080 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2002 | 153 | 0.080 |
Why?
|
| Interleukin-8 | 2 | 2010 | 696 | 0.080 |
Why?
|
| Genetic Techniques | 1 | 1992 | 428 | 0.080 |
Why?
|
| Genetic Heterogeneity | 1 | 2012 | 732 | 0.080 |
Why?
|
| Phenotype | 11 | 2009 | 16592 | 0.080 |
Why?
|
| Nucleic Acid Denaturation | 3 | 1994 | 110 | 0.080 |
Why?
|
| Exocytosis | 1 | 2010 | 320 | 0.080 |
Why?
|
| Immunoglobulins | 1 | 2012 | 852 | 0.080 |
Why?
|
| Optic Disk | 1 | 1993 | 421 | 0.080 |
Why?
|
| Gene Expression | 1 | 2021 | 7581 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 11904 | 0.080 |
Why?
|
| Fas Ligand Protein | 1 | 2008 | 216 | 0.080 |
Why?
|
| Diuretics | 1 | 1991 | 610 | 0.080 |
Why?
|
| Smoking | 4 | 2001 | 9053 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2014 | 1601 | 0.070 |
Why?
|
| Glutamic Acid | 1 | 2013 | 1176 | 0.070 |
Why?
|
| Remission, Spontaneous | 2 | 2010 | 384 | 0.070 |
Why?
|
| Animals | 14 | 2021 | 168475 | 0.070 |
Why?
|
| Amino Acid Substitution | 2 | 2003 | 1739 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2021 | 80647 | 0.070 |
Why?
|
| Sequence Deletion | 2 | 2003 | 1494 | 0.070 |
Why?
|
| Erythrocytes | 3 | 1992 | 2413 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 1997 | 2084 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 867 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2008 | 367 | 0.070 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2007 | 96 | 0.070 |
Why?
|
| Eating | 1 | 1993 | 1539 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 1994 | 1141 | 0.070 |
Why?
|
| Homozygote | 2 | 2003 | 1776 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2009 | 535 | 0.070 |
Why?
|
| Body Weight | 6 | 2004 | 4618 | 0.070 |
Why?
|
| DNA Transposable Elements | 2 | 2002 | 755 | 0.070 |
Why?
|
| Membrane Proteins | 3 | 2014 | 7859 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2006 | 247 | 0.070 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 691 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 1999 | 318 | 0.070 |
Why?
|
| C-Reactive Protein | 2 | 2008 | 3826 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2006 | 277 | 0.070 |
Why?
|
| Prediabetic State | 3 | 2006 | 545 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2012 | 9319 | 0.060 |
Why?
|
| Twin Studies as Topic | 1 | 2005 | 103 | 0.060 |
Why?
|
| Gene Deletion | 2 | 2006 | 2665 | 0.060 |
Why?
|
| Hypoglycemic Agents | 3 | 2012 | 3085 | 0.060 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2008 | 1126 | 0.060 |
Why?
|
| Glucose | 5 | 1995 | 4347 | 0.060 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2006 | 329 | 0.060 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 1924 | 0.060 |
Why?
|
| Cardiovascular Diseases | 5 | 2005 | 15502 | 0.060 |
Why?
|
| DNA Mutational Analysis | 3 | 2009 | 4111 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 4576 | 0.060 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2005 | 296 | 0.060 |
Why?
|
| Cross-Sectional Studies | 5 | 2015 | 26129 | 0.060 |
Why?
|
| Carrier Proteins | 3 | 2009 | 4937 | 0.060 |
Why?
|
| Chemokines | 1 | 2008 | 959 | 0.060 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 1134 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 1995 | 2496 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 2735 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 1 | 2009 | 1342 | 0.050 |
Why?
|
| Mice | 6 | 2021 | 81539 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2016 | 3549 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2003 | 287 | 0.050 |
Why?
|
| Hyperhomocysteinemia | 1 | 2003 | 118 | 0.050 |
Why?
|
| Skin | 2 | 2015 | 4484 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 2805 | 0.050 |
Why?
|
| Fathers | 3 | 2002 | 376 | 0.050 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1983 | 141 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 1993 | 2645 | 0.050 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 58984 | 0.050 |
Why?
|
| Cell Line | 2 | 2013 | 15601 | 0.050 |
Why?
|
| Heart | 1 | 2015 | 4404 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2005 | 754 | 0.050 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2002 | 186 | 0.050 |
Why?
|
| Health | 2 | 1982 | 398 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1983 | 294 | 0.050 |
Why?
|
| Analysis of Variance | 5 | 2007 | 6228 | 0.050 |
Why?
|
| Restriction Mapping | 1 | 2002 | 851 | 0.050 |
Why?
|
| Hypotension, Orthostatic | 1 | 1985 | 258 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2004 | 519 | 0.050 |
Why?
|
| Infant | 7 | 2011 | 36193 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6484 | 0.050 |
Why?
|
| Coronary Artery Disease | 2 | 1991 | 6403 | 0.050 |
Why?
|
| Methyltransferases | 1 | 2024 | 377 | 0.050 |
Why?
|
| Body Mass Index | 4 | 2006 | 12953 | 0.050 |
Why?
|
| Dimerization | 1 | 2002 | 891 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2007 | 2643 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 426 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 2 | 2003 | 4740 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2004 | 1163 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2002 | 705 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2013 | 5112 | 0.040 |
Why?
|
| Apolipoprotein E2 | 1 | 2000 | 135 | 0.040 |
Why?
|
| C-Peptide | 1 | 1982 | 440 | 0.040 |
Why?
|
| Glucagon | 1 | 1982 | 532 | 0.040 |
Why?
|
| Triglycerides | 2 | 1999 | 2461 | 0.040 |
Why?
|
| Myocardial Infarction | 6 | 1988 | 11461 | 0.040 |
Why?
|
| Imidazolidines | 1 | 1999 | 38 | 0.040 |
Why?
|
| Glucokinase | 1 | 2000 | 102 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 1 | 1999 | 183 | 0.040 |
Why?
|
| CpG Islands | 1 | 2024 | 1230 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2006 | 1742 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2010 | 2986 | 0.040 |
Why?
|
| Sex Factors | 9 | 2009 | 10554 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2013 | 8633 | 0.040 |
Why?
|
| Centromere | 1 | 1999 | 212 | 0.040 |
Why?
|
| Chromatography, Liquid | 2 | 2013 | 983 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2003 | 1699 | 0.040 |
Why?
|
| Genetic Testing | 3 | 2001 | 3537 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2000 | 418 | 0.040 |
Why?
|
| Tyrosine | 1 | 2002 | 1440 | 0.040 |
Why?
|
| Response Elements | 1 | 1999 | 309 | 0.040 |
Why?
|
| Bed Occupancy | 1 | 1978 | 38 | 0.040 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 1997 | 60 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 1999 | 557 | 0.040 |
Why?
|
| Diabetic Coma | 1 | 1977 | 8 | 0.040 |
Why?
|
| Sequence Alignment | 1 | 2002 | 2180 | 0.040 |
Why?
|
| Quantitative Trait Loci | 1 | 2006 | 2116 | 0.040 |
Why?
|
| Genes, Recessive | 1 | 2000 | 623 | 0.040 |
Why?
|
| Massachusetts | 4 | 2013 | 8833 | 0.040 |
Why?
|
| Cell Movement | 1 | 2009 | 5205 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 15843 | 0.040 |
Why?
|
| Endothelium | 1 | 2000 | 765 | 0.040 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2001 | 1136 | 0.030 |
Why?
|
| Lactates | 1 | 1977 | 405 | 0.030 |
Why?
|
| Morbidity | 1 | 1982 | 1752 | 0.030 |
Why?
|
| Comorbidity | 1 | 2011 | 10508 | 0.030 |
Why?
|
| Gels | 1 | 1997 | 420 | 0.030 |
Why?
|
| Heart Rate | 3 | 2015 | 4195 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2002 | 1363 | 0.030 |
Why?
|
| Protein Denaturation | 1 | 1995 | 242 | 0.030 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1996 | 370 | 0.030 |
Why?
|
| DNA-Cytosine Methylases | 1 | 1994 | 17 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2011 | 26202 | 0.030 |
Why?
|
| Phosphorylation | 3 | 2013 | 8321 | 0.030 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1996 | 269 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 1995 | 646 | 0.030 |
Why?
|
| Molecular Probes | 1 | 1996 | 309 | 0.030 |
Why?
|
| Aging | 2 | 2009 | 8710 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2014 | 64685 | 0.030 |
Why?
|
| Dietary Fats | 2 | 2010 | 1995 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 1997 | 400 | 0.030 |
Why?
|
| Codon | 1 | 1996 | 601 | 0.030 |
Why?
|
| Mortality | 1 | 2005 | 2902 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1994 | 777 | 0.030 |
Why?
|
| Software | 2 | 2005 | 4434 | 0.030 |
Why?
|
| Registries | 1 | 2010 | 8225 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 1995 | 441 | 0.030 |
Why?
|
| Immunoassay | 1 | 1997 | 745 | 0.030 |
Why?
|
| Isoelectric Focusing | 1 | 1993 | 150 | 0.030 |
Why?
|
| Amino Acids | 1 | 1999 | 1718 | 0.030 |
Why?
|
| RNA | 1 | 2003 | 2725 | 0.030 |
Why?
|
| Twins, Monozygotic | 1 | 2015 | 470 | 0.030 |
Why?
|
| Patient Education as Topic | 2 | 1983 | 2319 | 0.030 |
Why?
|
| Mothers | 2 | 2002 | 2198 | 0.030 |
Why?
|
| Multigene Family | 1 | 1996 | 1076 | 0.030 |
Why?
|
| Exercise | 3 | 1997 | 5890 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1994 | 1302 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 1983 | 1935 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1994 | 779 | 0.030 |
Why?
|
| Ophthalmoscopy | 1 | 1993 | 171 | 0.030 |
Why?
|
| Parents | 2 | 1997 | 3563 | 0.030 |
Why?
|
| Diet Records | 1 | 1993 | 427 | 0.020 |
Why?
|
| Genes, ras | 1 | 1995 | 654 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1999 | 6131 | 0.020 |
Why?
|
| Health Status | 2 | 1982 | 4077 | 0.020 |
Why?
|
| Statistics as Topic | 2 | 2002 | 2358 | 0.020 |
Why?
|
| Telomere | 1 | 1998 | 943 | 0.020 |
Why?
|
| Kynurenine | 1 | 2012 | 141 | 0.020 |
Why?
|
| Hemoglobins | 1 | 1997 | 1526 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 473 | 0.020 |
Why?
|
| Birth Order | 1 | 1991 | 95 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2000 | 2571 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 477 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 506 | 0.020 |
Why?
|
| Hemodynamics | 3 | 1992 | 4160 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 1625 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2013 | 2186 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2010 | 18255 | 0.020 |
Why?
|
| Electrophoresis, Capillary | 1 | 2010 | 63 | 0.020 |
Why?
|
| Glutamine | 1 | 2013 | 577 | 0.020 |
Why?
|
| HLA Antigens | 1 | 1995 | 1328 | 0.020 |
Why?
|
| Rats | 2 | 2005 | 23741 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 1995 | 2927 | 0.020 |
Why?
|
| United States | 9 | 2014 | 72340 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2005 | 14417 | 0.020 |
Why?
|
| Leukocytes | 1 | 1998 | 2026 | 0.020 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2009 | 35 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 1995 | 1154 | 0.020 |
Why?
|
| Diabetes, Gestational | 1 | 1999 | 1248 | 0.020 |
Why?
|
| Molecular Biology | 1 | 1992 | 576 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1995 | 2510 | 0.020 |
Why?
|
| Arginine | 1 | 2012 | 934 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2001 | 4415 | 0.020 |
Why?
|
| HLA-DR Antigens | 2 | 1986 | 602 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 13446 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2010 | 502 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 1988 | 328 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 615 | 0.020 |
Why?
|
| Luciferases | 1 | 2009 | 714 | 0.020 |
Why?
|
| Sodium | 2 | 1995 | 1588 | 0.020 |
Why?
|
| Urban Population | 4 | 1983 | 2036 | 0.020 |
Why?
|
| Collagen | 1 | 1995 | 2638 | 0.020 |
Why?
|
| Energy Intake | 2 | 1993 | 2134 | 0.020 |
Why?
|
| Myopia | 2 | 1986 | 253 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 435 | 0.020 |
Why?
|
| Weight Gain | 1 | 1997 | 2348 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 1995 | 5485 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 1986 | 129 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 1188 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 1997 | 5493 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 1978 | 1924 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 2006 | 416 | 0.020 |
Why?
|
| Death, Sudden, Cardiac | 1 | 1994 | 1555 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 1993 | 4853 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2000 | 5079 | 0.020 |
Why?
|
| Respiration | 1 | 1992 | 1656 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 6214 | 0.020 |
Why?
|
| 5' Untranslated Regions | 1 | 2006 | 256 | 0.020 |
Why?
|
| Lithium | 1 | 1988 | 596 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2000 | 12794 | 0.010 |
Why?
|
| Cadherins | 1 | 2009 | 903 | 0.010 |
Why?
|
| Biopsy | 2 | 2009 | 6766 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1991 | 1474 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 22174 | 0.010 |
Why?
|
| Heart Diseases | 1 | 1977 | 2781 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 1991 | 1779 | 0.010 |
Why?
|
| Infant Mortality | 1 | 1988 | 759 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 1971 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 1987 | 959 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 8181 | 0.010 |
Why?
|
| Renal Replacement Therapy | 1 | 2005 | 282 | 0.010 |
Why?
|
| ROC Curve | 1 | 2010 | 3578 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1993 | 2598 | 0.010 |
Why?
|
| Prevalence | 3 | 2002 | 15733 | 0.010 |
Why?
|
| Japan | 1 | 2006 | 1378 | 0.010 |
Why?
|
| Work Capacity Evaluation | 1 | 1982 | 44 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2009 | 5035 | 0.010 |
Why?
|
| Brazil | 1 | 2005 | 1230 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2457 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1975 | 6377 | 0.010 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 7 | 1 | 2001 | 4 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2006 | 1093 | 0.010 |
Why?
|
| Attitude to Health | 4 | 1983 | 2025 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1994 | 10090 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1993 | 4028 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 3733 | 0.010 |
Why?
|
| RNA Interference | 1 | 2009 | 2832 | 0.010 |
Why?
|
| Acetylcholine | 1 | 2002 | 629 | 0.010 |
Why?
|
| Patient Compliance | 2 | 1983 | 2690 | 0.010 |
Why?
|
| Fetal Death | 2 | 1995 | 435 | 0.010 |
Why?
|
| Forearm | 1 | 2002 | 427 | 0.010 |
Why?
|
| Contig Mapping | 1 | 1999 | 54 | 0.010 |
Why?
|
| Hepatocyte Nuclear Factor 3-gamma | 1 | 1999 | 10 | 0.010 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 1999 | 20 | 0.010 |
Why?
|
| Sequence Tagged Sites | 1 | 1999 | 96 | 0.010 |
Why?
|
| Chromosomes, Artificial, Yeast | 1 | 1999 | 113 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1999 | 422 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2001 | 2872 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1991 | 4471 | 0.010 |
Why?
|
| Coronary Vessels | 1 | 1991 | 3096 | 0.010 |
Why?
|
| Carrier State | 1 | 1983 | 523 | 0.010 |
Why?
|
| Pregnancy | 4 | 1999 | 29890 | 0.010 |
Why?
|
| GPI-Linked Proteins | 1 | 2001 | 470 | 0.010 |
Why?
|
| Chromosome Segregation | 1 | 2000 | 235 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 7593 | 0.010 |
Why?
|
| Metalloendopeptidases | 1 | 2001 | 393 | 0.010 |
Why?
|
| Chromosomes, Bacterial | 1 | 1999 | 281 | 0.010 |
Why?
|
| Phenformin | 1 | 1978 | 14 | 0.010 |
Why?
|
| Microcirculation | 1 | 2002 | 1272 | 0.010 |
Why?
|
| Binding Sites | 1 | 2006 | 6056 | 0.010 |
Why?
|
| Autoradiography | 1 | 1998 | 728 | 0.010 |
Why?
|
| Catecholamines | 1 | 1978 | 386 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2000 | 992 | 0.010 |
Why?
|
| Minority Groups | 1 | 2004 | 1203 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 3597 | 0.010 |
Why?
|
| Health Services | 1 | 1982 | 752 | 0.010 |
Why?
|
| Receptors, Immunologic | 1 | 2002 | 1410 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1999 | 1991 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 2005 | 1749 | 0.010 |
Why?
|
| DNA Restriction Enzymes | 1 | 1995 | 550 | 0.010 |
Why?
|
| Administration, Oral | 2 | 1990 | 4021 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2010 | 7968 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1995 | 866 | 0.010 |
Why?
|
| Physicians | 1 | 1992 | 4591 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 2910 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1995 | 526 | 0.010 |
Why?
|
| Imidazoles | 1 | 1999 | 1180 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2000 | 2707 | 0.010 |
Why?
|
| Glycosuria | 2 | 1985 | 44 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1978 | 1814 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2009 | 16990 | 0.010 |
Why?
|
| Mass Screening | 2 | 1992 | 5429 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2005 | 6241 | 0.010 |
Why?
|
| Disabled Persons | 1 | 1982 | 1226 | 0.010 |
Why?
|
| Fasting | 1 | 1997 | 1603 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 4431 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1991 | 615 | 0.010 |
Why?
|
| Abortion, Spontaneous | 1 | 1995 | 533 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1995 | 1078 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2002 | 11076 | 0.000 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 3713 | 0.000 |
Why?
|
| Lipids | 1 | 1999 | 3341 | 0.000 |
Why?
|
| Cell Division | 1 | 1995 | 4465 | 0.000 |
Why?
|
| Diagnostic Errors | 1 | 1975 | 1265 | 0.000 |
Why?
|
| Angiotensin II | 1 | 1989 | 849 | 0.000 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 1989 | 540 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1990 | 2217 | 0.000 |
Why?
|
| Life Expectancy | 1 | 1992 | 1243 | 0.000 |
Why?
|
| Algorithms | 1 | 2005 | 14033 | 0.000 |
Why?
|
| Refractive Errors | 1 | 1986 | 147 | 0.000 |
Why?
|
| Pulmonary Embolism | 1 | 1978 | 2567 | 0.000 |
Why?
|
| Heart Failure | 1 | 1988 | 11671 | 0.000 |
Why?
|
| Length of Stay | 1 | 1978 | 6426 | 0.000 |
Why?
|
| Kinetics | 1 | 1990 | 6374 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 10212 | 0.000 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1987 | 1119 | 0.000 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1985 | 1435 | 0.000 |
Why?
|
| Health Behavior | 1 | 1992 | 2644 | 0.000 |
Why?
|
| Occupations | 1 | 1982 | 515 | 0.000 |
Why?
|
| Health Care Costs | 1 | 1992 | 3242 | 0.000 |
Why?
|
| Medical Records | 1 | 1984 | 1408 | 0.000 |
Why?
|
| Education | 1 | 1982 | 537 | 0.000 |
Why?
|
| Motivation | 1 | 1985 | 2006 | 0.000 |
Why?
|
| Hospitalization | 1 | 1975 | 10721 | 0.000 |
Why?
|
| Social Class | 1 | 1982 | 2004 | 0.000 |
Why?
|
| Data Collection | 1 | 1982 | 3322 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1983 | 2775 | 0.000 |
Why?
|
| Hypoglycemia | 1 | 1978 | 883 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1978 | 8002 | 0.000 |
Why?
|
| Research Design | 1 | 1975 | 6180 | 0.000 |
Why?
|